Tag: GW Pharmaceuticals
FDA Approves More Uses for Epidiolex
CARLSBAD, Calif. – Epidiolex, the first FDA-approved prescription medication containing a cannabis derivative, has received approval from the U.S. Food and Drug Administration for...
Key DEA Change Could Make Cannabinoid-Based Medicine More Accessible
Washington D.C. – The Drug Enforcement Administration (DEA) is making policy changes that could make it easier for patients to access Epidiolex.
Epidiolex, produced...
New Frontier Webinar Focuses on Risk, Opportunity Amid Coronavirus Crisis
Marketing data firm New Frontier Data yesterday hosted a day-long webinar on the effect of the coronavirus (COVID-19) crisis on the global cannabis and...
Dept. of Transportation Issues Compliance Notice on CBD Use
WASHINGTON, D.C. – The U.S. Department of Transportation (DOT) issued a compliance notice on Tuesday addressing use of CBD-infused products for “safety sensitive employees.”
Employees...
FDA Provides Update on CBD Position
WASHINGTON, D.C. – The Food and Drug Administration (FDA) has provided an update regarding its stance on hemp and CBD. Although hemp containing less...
Risky Business: CBD Health Claims Can Land Marketers in Federal Trouble
Marketing CBD products presents a quandary. CBD doesn’t cause an altered mental state, so it seems obvious products containing the substance are intended for...
Disillusioned with Big Pharma, Consumers Take Control of Their Own Health
The cannabinoid tetrahydrocannabinol (THC), the psychoactive compound in cannabis, used to get all the attention. But cannabidiol, more commonly known as CBD, has gained...
